INTERAKSI FARMAKOGENOMIK DALAM POLIFARMASI OBAT ANTIHIPERTENSI DAN KAITANNYA DENGAN KOMPLIKASI INTRADIALISIS PADA PASIEN GAGAL GINJAL KRONIK DENGAN HEMODIALISA : PENDEKATAN SYSTEMATIC LITERATURE REVIEW
DOI:
https://doi.org/10.23969/jp.v11i01.41113Keywords:
pharmacogenomics; polypharmacy; antihypertensive drugs; hemodialysis; intradialytic complicationsAbstract
This study aims to synthesize scientific evidence on pharmacogenomic interactions in antihypertensive polypharmacy and their association with intradialytic complications among chronic kidney disease (CKD) patients undergoing hemodialysis using a Systematic Literature Review (SLR) approach. A systematic literature search was conducted across PubMed, Scopus, Google Scholar, and Wiley Online Library for publications from 2017 to 2025, following the PRISMA guidelines and the PICO framework. A total of 30 articles met the inclusion criteria and were synthesized narratively. The findings indicate that antihypertensive polypharmacy is highly prevalent in the hemodialysis population, with an average use of ≥5–10 medications. The most frequently reported pharmacogenomic interactions involved phase I metabolic genes, particularly CYP2D6 and CYP2C9, influencing responses to beta-blockers and angiotensin receptor blockers (ARBs). Drug–drug–gene interactions in intensive polypharmacy conditions were associated with increased risks of intradialytic hypotension, intradialytic hypertension, bradycardia, electrolyte disturbances, and reduced quality of life. This synthesis highlights that intradialytic complications are influenced not only by drug class or dosing time but also by a combination of genetic factors, renal function, and medication burden. The integration of pharmacogenomic approaches, comprehensive polypharmacy evaluation, and clinical pharmacist involvement holds potential to improve patient safety and hemodynamic stability in hemodialysis patients.
Downloads
References
Abah, M. A., Chijioke, P. C., Oladosu, M. A., Balogun, O. A., Yakub, O. Z., Patience, O., & Adeniyi, R. A. (2025). Cardiovascular effects of commonly prescribed antihypertensive drugs in elderly patients: A comprehensive review. International Journal of Advanced Biological and Biomedical Research, 13(6), 668–684.
Al-Khulaifi, A., Khatib, M., Ali, E., Ali, M. Y., & Danjuma, M. I. M. U. (2023). What is polypharmacy in patients with chronic kidney disease? A systematic review. Clinical Therapeutics, 45(11), e217–e221.
AlJassas, S. M., Alzaidi, N. A., Algharqan, S. M., Aljawad, S. H., Alsofyani, B. M., & Hadadi, F. A. (2024). Evaluating the impact of drug–drug interactions in polypharmacy strategies for safe medication management. JOHS, 4(12), 1051–1056.
Ameer, O. Z. (2022). Hypertension in chronic kidney disease: What lies behind the scene. Frontiers in Pharmacology, 13, 949260.
Anfinogenova, N. D., Novikova, O. M., Trubacheva, I. A., Efimova, E. V., Chesalov, N. P., Ussov, W. Y., & Repin, A. N. (2023). Prescribed versus taken polypharmacy and drug–drug interactions in older cardiovascular patients during the COVID-19 pandemic: Observational cross-sectional analytical study. Journal of Clinical Medicine, 12(15), 5061.
Bektay, M. Y., Buker Cakir, A., Gursu, M., Kazancioglu, R., & Izzettin, F. V. (2024). An assessment of different decision support software from the perspective of potential drug–drug interactions in patients with chronic kidney diseases. Pharmaceuticals, 17(5), 562.
Calleja, L., Glass, B. D., Cairns, A., & Taylor, S. (2023). Pharmacist-led interventions for medication adherence in patients with chronic kidney disease: A scoping review. Pharmacy, 11(6), 185.
Chang, T. I., Tatoian, E. T., Montez-Rath, M. E., & Chertow, G. M. (2021). Timing of antihypertensive medications on key outcomes in hemodialysis: A cluster randomized trial. Kidney360, 2(11), 1752–1760.
Chen, T. Y., Hsieh, M. H. C., Su, F. Y., Li, C. Y., Wang, M. C., Tseng, C. C., & Lai, E. C. C. (2025). Risk of intradialytic hypotension among different antihypertensives in haemodialysis patients. Clinical Kidney Journal, 18(6), sfaf159.
Cicero, A. F., Fogacci, F., Cincione, R. I., Tocci, G., & Borghi, C. (2021). Clinical effects of xanthine oxidase inhibitors in hyperuricemic patients. Medical Principles and Practice, 30(2), 122–130.
Dean, L., & Kane, M. (2025). Metoprolol therapy and CYP2D6 genotype. Medical Genetics Summaries.
Deb, S., Reeves, A. A., Hopefl, R., & Bejusca, R. (2021). ADME and pharmacokinetic properties of remdesivir: Its drug interaction potential. Pharmaceuticals, 14(7), 655.
Diaconu, C. C., Cozma, M. A., Dobrică, E. C., Gheorghe, G., Jichitu, A., Ionescu, V. A., & Găman, M. A. (2021). Polypharmacy in the management of arterial hypertension—Friend or foe? Medicina, 57(12), 1288.
Eadon, M. T., Maddatu, J., Moe, S. M., Sinha, A. D., Ferreira, R. M., Miller, B. W., & Skaar, T. C. (2022). Pharmacogenomics of hypertension in CKD: The CKD-PGX study. Kidney360, 3(2), 307–316.
Galistiani, G. F., Ratri, E. P., & Wahyono, D. (2025). Polifarmasi dan interaksi obat pada pasien gagal ginjal kronis yang menjalani hemodialisa. PHARMACY: Jurnal Farmasi Indonesia, 55–59.
Ha, X., Gao, X., Teng, W., Zhang, J., Maimaiti, Z., Yalikun, D., & Jiang, H. (2025). Pharmacogenomics-guided precision therapy for chronic kidney disease with resistant hypertension: A prospective cohort study. Kidney and Blood Pressure Research.
Harsh, S., Tripathi, S., Venuturumilli, R., Shanmuga Priya, K., Reddy, G. H. V., Mukherjee, B., & Lakhani, H. A. (2025). Adverse drug reactions and drug interactions in multimorbid patients: A review of current evidence. Cureus, 17(11), e97640.
Iatridi, F., Theodorakopoulou, M. P., Karagiannidis, A. G., & Sarafidis, P. (2025). Intradialytic hypertension in maintenance hemodialysis. Current Hypertension Reports, 27(1), 1.
Kalantar-Zadeh, K., Lockwood, M. B., Rhee, C. M., Tantisattamo, E., Andreoli, S., Balducci, A., & Li, P. K. T. (2022). Patient-centred approaches for the management of unpleasant symptoms in kidney disease. Nature Reviews Nephrology, 18(3), 185–198.
Kanbay, M., Ertuglu, L. A., Afsar, B., Ozdogan, E., Siriopol, D., Covic, A., & Ortiz, A. (2020). An update review of intradialytic hypotension: Concept, risk factors, clinical implications and management. Clinical Kidney Journal, 13(6), 981–993.
Kitamura, M., Yamaguchi, K., Ota, Y., Notomi, S., Komine, M., Etoh, R., & Nishino, T. (2021). Prognostic impact of polypharmacy by drug essentiality in patients on hemodialysis. Scientific Reports, 11(1), 24238.
Kurniawan, H. I., Sciacca, K. R., Wachterman, M. W., & Gelfand, S. L. (2024). Clinical practice review: Outpatient palliative care for the geriatric chronic kidney disease population. Annals of Palliative Medicine, 13(4), 93847–93947.
Liabeuf, S., Berdougo-Tritz, J., Augey, L., Mbarek, A., Jadoul, M., Deray, G., & Massy, Z. A. (2025). Drug exposure in chronic kidney disease: It is not just about the glomerular filtration rate. Fundamental & Clinical Pharmacology, 39(4), 1–10.
Malfertheiner, P., Kandulski, A., & Venerito, M. (2017). Proton-pump inhibitors: Understanding the complications and risks. Nature Reviews Gastroenterology & Hepatology, 14(12), 697–710.
Mende, J., Kartikawati, N. D., Titami, A., & Mahmuda, H. (2025). Principles of dose adjustment in patients with chronic kidney failure. Jurnal Farmasi Sains dan Praktis, 115–126.
Naseralallah, L., Khatib, M., Al-Khulaifi, A., & Danjuma, M. (2023). Prevalence and global trends of polypharmacy in patients with chronic kidney disease: A systematic review and meta-analysis. Frontiers in Pharmacology, 14, 1122898.
Okpechi, I. G., Tinwala, M. M., Muneer, S., Zaidi, D., Ye, F., Hamonic, L. N., & Bello, A. K. (2021). Prevalence of polypharmacy and associated adverse health outcomes in adult patients with chronic kidney disease: Protocol for a systematic review and meta-analysis. Systematic Reviews, 10(1), 198.
Onan, E., Paydas, S., Balal, M., Taşkapan, H., & Bozacı, İ. (2025). Polypharmacy and accompanying comorbid conditions in kidney transplant recipients: A retrospective study. Journal of Cukurova Anesthesia and Surgical Sciences, 8(3), 313–319.
Oosthuizen, D., & Sturrock, E. D. (2022). Exploring the impact of ACE inhibition in immunity and disease. Journal of the Renin-Angiotensin-Aldosterone System, 2022, 9028969.
Oosting, I. J., Colombijn, J. M., Kaasenbrood, L., Liabeuf, S., Laville, S. M., Hooft, L., & Vernooij, R. W. (2024). Polypharmacy in patients with CKD: A systematic review and meta-analysis. Kidney360, 5(6), 841–850.
Pasangka, I. T. (2017). Identifikasi potensi interaksi obat pada pasien gagal ginjal rawat inap di RSUP Prof. Dr. RD Kandou Manado. PHARMACON, 6(4).
Rachmayanti, A. S., Suhera, S., Haryani, R., Sammulia, S. F., Meilandra, R., & Agnesfebrianti, A. (2024). Gambaran potensi interaksi obat pada resep polifarmasi pasien lansia di rumah sakit Badan Pengusahaan Batam. Jurnal Surya Medika, 10(1), 199–204.
Ratnasari, P. M. D., Dhrik, M., Rizqy, L. K. R., & Devi, N. K. D. R. (2024). Evaluasi kesesuaian dosis dan interaksi obat potensial pada pasien gagal ginjal kronik di rumah sakit swasta Denpasar Bali. Jurnal Ilmiah Medicamento, 10(2), 109–123.
Siddiqi, N., & Shatat, I. F. (2020). Antihypertensive agents: A long way to safe drug prescribing in children. Pediatric Nephrology, 35(11), 2049–2065.
Simões e Silva, A. C., Miranda, A. S., Rocha, N. P., & Teixeira, A. L. (2019). Neuropsychiatric disorders in chronic kidney disease. Frontiers in Pharmacology, 10, 932.
Tomson, C. R., Cheung, A. K., Mann, J. F., Chang, T. I., Cushman, W. C., Furth, S. L., & Sarnak, M. J. (2021). Management of blood pressure in patients with chronic kidney disease not receiving dialysis: Synopsis of the 2021 KDIGO clinical practice guideline. Annals of Internal Medicine, 174(9), 1270–1281.
Ugwendum, D., Rahman, E. U., Farah, F., Forsah, S., Mahmoud, M., & Agbor, D. B. A. (2024). Polypharmacy in patients with chronic kidney disease with cardiovascular disease comorbidities: A systematic review. International Clinical Medical Case Reports Journal, 3(2), 1–14.
Uchiyama, K., Shibagaki, K., Yanai, A., Kusahana, E., Nakayama, T., Morimoto, K., & Itoh, H. (2021). Seasonal variation and predictors of intradialytic blood pressure decline: A retrospective cohort study. Hypertension Research, 44(11), 1417–1427.
Vondracek, S. F., Teitelbaum, I., & Kiser, T. H. (2021). Principles of kidney pharmacotherapy for the nephrologist: Core curriculum 2021. American Journal of Kidney Diseases, 78(3), 442–458.
Westergaard, N., Baltzer Houlind, M., Christrup, L. L., Juul-Larsen, H. G., Strandhave, C., & Olesen, A. E. (2024). Use of drugs with pharmacogenomics (PGx)-based dosing guidelines in a Danish cohort of persons with chronic kidney disease, both on dialysis and not on dialysis: Perspectives for prescribing optimization. Basic & Clinical Pharmacology & Toxicology, 134(4), 531–542.
Wolf, U. (2024). A drug safety briefing (II) in transplantation: From real-world individual pharmacotherapy management to prevent patient and graft from polypharmacy risks at the very earliest stage. Pharmaceuticals, 17(3), 294.
Zoccali, C., Mallamaci, F., Lightstone, L., Jha, V., Pollock, C., Tuttle, K., & Vanholder, R. (2024). A new era in the science and care of kidney diseases. Nature Reviews Nephrology, 20(7), 460–472.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Pendas : Jurnal Ilmiah Pendidikan Dasar
This work is licensed under a Creative Commons Attribution 4.0 International License.
